Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 4/2015

01-12-2015 | Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Cancer in the HIV-Infected Host: Epidemiology and Pathogenesis in the Antiretroviral Era

Authors: Cristina Brickman, Joel M. Palefsky

Published in: Current HIV/AIDS Reports | Issue 4/2015

Login to get access

Abstract

Cancer and HIV are inextricably linked. Although the advent of antiretroviral therapy has led to a marked decline in the incidence of malignancies classically linked to immunosuppression (AIDS-defining malignancies, or ADMs), this decrease has been accompanied by a concomitant rise in the incidence of other malignancies (non-AIDS-defining malignancies, or NADMs). Population-based cancer registries provide key information about cancer epidemiology in people living with HIV (PLWH) within resource-rich countries. The risk for NADMs is elevated in PLWH compared with the general population, particularly for lung and anal cancers. Contributory factors include tobacco use, coinfection with oncogenic viruses such as human papillomavirus, and potentially direct effects of HIV itself. Data from resource-poor countries are limited and highlight the need for more studies in countries where the majority of PLWH reside. Strategies for early cancer detection and/or prevention are necessary in PLWH.
Literature
1.
Centers for Disease, C. Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men—New York City and California. MMWR Morb Mortal Wkly Rep. 1981;30(25):305–8.
2.
Centers for Disease, C. Revision of the case definition of acquired immunodeficiency syndrome for national reporting—United States. MMWR Morb Mortal Wkly Rep. 1985;34(25):373–5.
3.
Centers for Disease, C. and Prevention. Impact of the expanded AIDS surveillance case definition on AIDS case reporting—United States, first quarter, 1993. MMWR Morb Mortal Wkly Rep. 1993;42(16):308–10.
4.
Biggar RJ et al. AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst. 2007;99(12):962–72.CrossRefPubMed
5.
Franceschi S et al. Kaposi sarcoma incidence in the swiss HIV cohort study before and after highly active antiretroviral therapy. Br J Cancer. 2008;99(5):800–4.PubMedCentralCrossRefPubMed
6.
Polesel J et al. Non-Hodgkin lymphoma incidence in the swiss HIV cohort study before and after highly active antiretroviral therapy. AIDS. 2008;22(2):301–6.CrossRefPubMed
7.•
Morlat P et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS. 2014;28(8):1181–91. Data from large French survey that summarizes causes of death in PLWH in the modern, post-ART era.CrossRefPubMed
8.••
Robbins HA, et al. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst, 2015. 107(4). Most current HACM data on epidemiology of cancer among PLWH in the U.S. Uses SEER registry data to compares incidence of cancer among HIV-infected people to the general population
9.••
Robbins HA et al. Epidemiologic contributions to recent cancer trends among HIV-infected people in the United States. AIDS. 2014;28(6):881–90. HACM data to evaluate incidence of cancer among PLWH over time and to assess the effect of (i) the age distribution of PLWH (ii) changes in incidence in the general population and (iii) HIV infection iteself, on these time trends.CrossRefPubMed
10.••
Hleyhel M et al. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis. 2013;57(11):1638–47. Updated data from the French Hospital National Database on HIV showing changes in the incidence of ADMs over time.CrossRefPubMed
11.••
Hleyhel M et al. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS. 2014;28(14):2109–18. Updated data from the French Hospital National Database on HIV showing changes in the incidence of NADMs over time.CrossRefPubMed
12.
13.
14.
Clifford GM et al. Cancer risk in the swiss HIV cohort study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425–32.CrossRefPubMed
15.
Patel P et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148(10):728–36.CrossRefPubMed
16.
van Leeuwen MT et al. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS. 2009;23(16):2183–90.PubMedCentralCrossRefPubMed
17.
Franceschi S et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the swiss HIV cohort study. Br J Cancer. 2010;103(3):416–22.PubMedCentralCrossRefPubMed
18.
19.
Silverberg MJ et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20(12):2551–9.PubMedCentralCrossRefPubMed
20.
Parkin DM. The evolution of the population-based cancer registry. Nat Rev Cancer. 2006;6(8):603–12.CrossRefPubMed
21.
Chen M et al. Prevalence of undiagnosed HIV infection among persons aged >/=13 years—national HIV surveillance system, United States, 2005–2008. MMWR Morb Mortal Wkly Rep. 2012;61:57–64.PubMed
22.
Cutrell J, Bedimo R. Non-AIDS-defining cancers among HIV-infected patients. Curr HIV/AIDS Rep. 2013;10(3):207–16.CrossRefPubMed
23.
Engels EA et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123(1):187–94.CrossRefPubMed
24.
Bouvard V et al. A review of human carcinogens—part B: biological agents. Lancet Oncol. 2009;10(4):321–2.CrossRefPubMed
25.
(UNAIDS), J.U.N.P.o.H.A., Global Report: UNAIDS report on the global AIDS epidemic 2013. 2013: Geneva, Switzerland.
26.•
Mbulaiteye SM et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-cancer registry match study. Int J Cancer. 2006;118(4):985–90. One of the few available linkage studies in sub-Saharan Africa: linked records of PLWH in Kyadondo County to the Kampala Cancer registry in Uganda.CrossRefPubMed
27.
Akarolo-Anthony SN et al. Cancer burden among HIV-positive persons in Nigeria: preliminary findings from the Nigerian AIDS-cancer match study. Infect Agent Cancer. 2014;9(1):1.PubMedCentralCrossRefPubMed
28.
Casper C. The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med. 2011;62:157–70.CrossRefPubMed
29.
30.
Ferlay J, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. 2013; Available from: http://​globocan.​iarc.​fr, accessed on July 12th 2015.
31.
Dhir AA et al. Spectrum of HIV/AIDS related cancers in India. Cancer Causes Control. 2008;19(2):147–53.CrossRefPubMed
32.
Pinzone MR et al. Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection. Semin Oncol. 2015;42(2):258–71.CrossRefPubMed
33.
34.
Secretan B et al. A review of human carcinogens—part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol. 2009;10(11):1033–4.CrossRefPubMed
35.
Mdodo R et al. Cigarette smoking prevalence among adults with HIV compared with the general adult population in the United States: cross-sectional surveys. Ann Intern Med. 2015;162(5):335–44.CrossRefPubMed
36.•
Helleberg M et al. Risk of cancer among HIV-infected individuals compared to the background population: impact of smoking and HIV. AIDS. 2014;28(10):1499–508. Danish study that calculates the impact of smoking on cancers in PLWH, including the population attributable fraction.CrossRefPubMed
37.
38.
Engels EA et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006;24(9):1383–8.CrossRefPubMed
39.
Hessol NA et al. Lung cancer incidence and survival among HIV-infected and uninfected women and men. AIDS. 2015;29(10):1183–93.CrossRefPubMed
40.
McGinnis KA et al. Hepatocellular carcinoma and non-Hodgkin’s lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol. 2006;24(31):5005–9.CrossRefPubMed
41.
De Martel, C, et al. Cancers attributable to infections among adults with HIV in the United States. AIDS, 2015.
42.
43.
Brickman C, Palefsky JM. Human papillomavirus in the HIV-infected host: epidemiology and pathogenesis in the antiretroviral era. Curr HIV/AIDS Rep. 2015;12(1):6–15.CrossRefPubMed
44.
Martin JN et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med. 1998;338(14):948–54.CrossRefPubMed
45.••
3rd Lo Re V et al. Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med. 2014;160(6):369–79. Large cohort study using data from the Veterans Association Shows that patients with HIV/HCV have greater rates of hepatic decompensation than HCV monoinfection, despite use of antiretrovirals to effectively suppress HIV.PubMed
46.
Balfour Jr HH et al. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6–19 years in the United States and factors affecting its acquisition. J Infect Dis. 2013;208(8):1286–93.CrossRefPubMed
47.
Thompson LD et al. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol. 2004;121(5):727–38.CrossRefPubMed
48.
49.
Romani B, Engelbrecht S, Glashoff RH. Functions of Tat: the versatile protein of human immunodeficiency virus type 1. J Gen Virol. 2010;91(Pt 1):1–12.CrossRefPubMed
50.
Kim RH et al. HIV-1 Tat enhances replicative potential of human oral keratinocytes harboring HPV-16 genome. Int J Oncol. 2008;33(4):777–82.PubMed
51.•
Tugizov SM et al. HIV-associated disruption of mucosal epithelium facilitates paracellular penetration by human papillomavirus. Virology. 2013;446(1–2):378–88. In vitro study showing how HIV-derived tat and gp120 disrupt epithelial tight-cell junctions which allow HPV pseudovirion infection of the basal cell l epithelium.CrossRefPubMed
52.
53.
Guiguet M et al. Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol. 2009;10(12):1152–9.CrossRefPubMed
54.
Bruyand M et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis. 2009;49(7):1109–16.PubMedCentralCrossRefPubMed
55.
Pacheco YM et al. Increased risk of non-AIDS-related events in HIV subjects with persistent low CD4 counts despite cART in the CoRIS cohort. Antiviral Res. 2015;117:69–74.CrossRefPubMed
56.•
Piketty C et al. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. J Clin Oncol. 2012;30(35):4360–6. Data from French Hospital National Database on HIV on recent incidence rates of anal cancer in PLWH.CrossRefPubMed
57.
58.
59.
60.
Marks MA et al. Markers of microbial translocation and risk of AIDS-related lymphoma. AIDS. 2013;27(3):469–74.CrossRefPubMed
61.•
French MA et al. Serum immune activation markers are persistently increased in patients with HIV infection after 6 years of antiretroviral therapy despite suppression of viral replication and reconstitution of CD4+ T cells. J Infect Dis. 2009;200(8):1212–5. Shows that inflammation persists in PLWH despite effective ART.CrossRefPubMed
62.
Neuhaus J et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12):1788–95.PubMedCentralCrossRefPubMed
63.•
Borges AH et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS. 2013;27(9):1433–41. Combines data from the control groups of 3 clinical trials in the U.S. to evaluate the risk of elevated inflammatory markers on the prospective risk of cancer Shows that activated inflammation and coagulation pathways are associated with increased cancer risk during HIV infection.PubMedCentralCrossRefPubMed
64.
Vendrame E et al. Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk. Cancer Epidemiol Biomarkers Prev. 2014;23(2):343–9.PubMedCentralCrossRefPubMed
65.
66.
Kawabata S et al. Impact of HIV on lung tumorigenesis in an animal model. AIDS. 2015;29(5):633–5.PubMed
67.••
Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med. 2010;153(7):452–60. One of the first papers to show that earlier age at cancer diagnosis in PLWH is largely due to differences in underlying age distribution compared to the general population, rather than an inherent effect of HIV itself.PubMedCentralCrossRefPubMed
68.
Althoff KN et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis. 2015;60(4):627–38.CrossRefPubMed
69.••
Coghill AE et al. Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol. 2015;33(21):2376–83. HACM data that shows how cancer mortality in PLWH is elevated compared to the general population.CrossRefPubMed
70.
Shiels MS et al. Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients. Cancer. 2015;121(12):2063–71.CrossRefPubMed
71.••
Marcus JL, et al. Survival Among HIV-Infected and HIV-Uninfected Individuals with Common Non-AIDS-Defining Cancers. Cancer Epidemiol Biomarkers Prev, 2015. Kaiser data that also shows increased cancer mortality in PLWH compared to non-HIV infected individuals
72.••
Suneja G et al. Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol. 2014;32(22):2344–50. One of few available papers to evaluate treatment of cancer in PLWH Shows that PLWH are less likely to receive cancer treatment.PubMedCentralCrossRefPubMed
73.
74.
Lohse N et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med. 2007;146(2):87–95.CrossRefPubMed
75.
Montoto S et al. HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. J Clin Oncol. 2012;30(33):4111–6.CrossRefPubMed
76.
White EC, et al. Comparison of Toxicity and Treatment Outcomes in HIV-positive Versus HIV-negative Patients With Squamous Cell Carcinoma of the Anal Canal. Am J Clin Oncol, 2014.
77.
Moyer VA, U.S.P.S.T. Force. Screening for lung cancer: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2014;160(5):330–8.CrossRefPubMed
78.
79.
National Lung Screening Trial Research, T. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.CrossRef
80.
81.
Park IU, Palefsky JM. Evaluation and management of anal intraepithelial neoplasia in HIV-negative and HIV-positive men who have sex with men. Curr Infect Dis Rep. 2010;12(2):126–33.PubMedCentralCrossRefPubMed
82.
Adefuye PO et al. Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa. Vaccine. 2013;31 Suppl 5:F53–9.CrossRefPubMed
83.
Adebamowo CA et al. Challenges in the detection, prevention, and treatment of HIV-associated malignancies in low- and middle-income countries in Africa. J Acquir Immune Defic Syndr. 2014;67 Suppl 1:S17–26.PubMedCentralCrossRefPubMed
Metadata
Title
Cancer in the HIV-Infected Host: Epidemiology and Pathogenesis in the Antiretroviral Era
Authors
Cristina Brickman
Joel M. Palefsky
Publication date
01-12-2015
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 4/2015
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-015-0283-7

Other articles of this Issue 4/2015

Current HIV/AIDS Reports 4/2015 Go to the issue

HIV and Technology (J Simoni and K Horvath, Section Editors)

The Roles of Technology in Primary HIV Prevention for Men Who Have Sex with Men

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Tobacco Use, Use Disorders, and Smoking Cessation Interventions in Persons Living With HIV

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review

HIV and Technology (J Simoni and K Horvath, Section Editors)

Cell Phone-Based and Adherence Device Technologies for HIV Care and Treatment in Resource-Limited Settings: Recent Advances

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

HIV and Technology (J Simoni and K Horvath, Section Editors)

Youth, Technology, and HIV: Recent Advances and Future Directions
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits